25977-23-5

Basic information

• Product Name: (5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL
• Synonyms: (5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL;CHEMBRDG-BB 4010305;(5-methyl-1,2,4-oxadiazol-3-yl)methanol(SALTDATA: FREE)
• CAS NO: 25977-23-5
• Molecular Formula: C₄H₆N₂O₂
• Molecular Weight: 114.1
• Mol File: 25977-23-5.mol

Chemical Properties

• Boiling Point: 248.2 °C at 760 mmHg
• Flash Point: 103.9 °C
• Appearance: /
• Density: 1.285 g/cm³
• Vapor Pressure: 0.013mmHg at 25°C
• Refractive Index: 1.497
• PKA: 12.07±0.10(Predicted)
• CAS DataBase Reference: (5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL(25977-23-5)
• EPA Substance Registry System: (5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL(25977-23-5)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 25977-23-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL is used as a building block for the synthesis of various pharmaceuticals due to its diverse biological activities and potential pharmacological properties, contributing to the development of new drugs with improved therapeutic effects.
Used in Agrochemical Industry:
(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL is used as a building block in the synthesis of agrochemicals, such as pesticides and herbicides, leveraging its biological activities to enhance crop protection and yield.
Used in Materials Industry:
(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL is used as a component in the development of new materials, taking advantage of its chemical properties to create innovative products with unique characteristics.
Used in Antimicrobial Applications:
(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL is used as an antimicrobial agent for its potential to inhibit the growth of various microorganisms, offering a solution for controlling infections and maintaining hygiene in different settings.
Used in Antifungal Applications:
(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL is used as an antifungal agent, leveraging its potential to combat fungal infections, which is particularly useful in agricultural and medical applications.
Used in Antiviral Applications:
(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHANOL is used as an antiviral agent, showing promise in inhibiting viral replication and activity, which can be beneficial in the development of treatments for various viral diseases.

InChI:InChI=1/C4H6N2O2/c1-3-5-4(2-7)6-8-3/h7H,2H2,1H3

Upstream product

• 40699-38-5 5-methyl-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester 
• 1217428-98-2 ethyl 2-oximinooxamate 
• 108-24-7 acetic anhydride 
• 14337-43-0 ethyl 2-chloro-2-(hydroxyimino)acetate 

Downstream Products

• 1192-80-9 3-(chloromethyl)-5-methyl-1,2,4-oxadiazole 
• 959406-40-7 3-(bromomethyl)-5-methyl-1,2,4-oxadiazole 
• 1083300-23-5 5-methyl-1,2,4-oxadiazole-3-carboxaldehyde 

Relevant articles and documents

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

Amino-Containing Compounds Which Inhibit Memapsin 2 Beta-Secretase Activity and Methods of Use Thereof

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

BICYCLIC COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.

Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4- triazolo[3,4-a]phthalazines as GABAA receptor agonists at the α3 subunit

We have previously identified the 7,8,9,10-tetrahydro-7,10-ethano-1,2,4- triazolo[3,4-a]phthalazine (1) as a potent partial agonist for the 0.3 receptor subtype with 5-fold selectivity in binding affinity over α1. This paper describes a detailed investigation of the substituents on this core structure at both the 3- and 6-positions. Despite evaluating a wide range of groups, the maximum selectivity that could be achieved in terms of affinity for the α3 subtype over the α1 subtype was 12-fold (for 57). Although most analogues showed no selectivity in terms of efficacy, some did show partial agonism at α1 and antagonism at α3 (e.g., 25 and 75). However, two analogues tested (93 and 96), both with triazole substituents in the 6-position, showed significantly higher efficacy for the α3 subtype over the α1 subtype. This was the first indication that selectivity in efficacy in the required direction could be achieved in this series.